Literature DB >> 12093968

Uses of drugs not described in the package insert (off-label uses).

.   

Abstract

New regulatory initiatives have been designed to ensure that new drugs and biologicals include adequate pediatric labeling for the claimed indications at the time of, or soon after, approval. However, because such labeling may not immediately be available, off-label use (or use that is not included in the approved label) of therapeutic agents is likely to remain common in the practice of pediatrics. This policy statement was written to address questions practitioners have regarding off-label use. The purpose of off-label use is to benefit the individual patient. Practitioners may use their professional judgment to determine these uses. Practitioners should understand that the Food and Drug Administration does not regulate off-label use.

Entities:  

Mesh:

Year:  2002        PMID: 12093968

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

1.  The awareness among paediatricians of off-label prescribing in children: a survey of Italian hospitals.

Authors:  Federico Marchetti; Jenny Bua; Alessandro Ventura; Luigi D Notarangelo; Salvatore Di Maio; Giuseppina Migliore; Maurizio Bonati
Journal:  Eur J Clin Pharmacol       Date:  2006-11-24       Impact factor: 2.953

2.  Paediatric clinical pharmacology: at the beginning of a new era.

Authors:  Kalle Hoppu
Journal:  Eur J Clin Pharmacol       Date:  2007-10-31       Impact factor: 2.953

3.  Challenges in international pediatric pharmacology: a milestone meeting in Shanghai.

Authors:  Stuart MacLeod; Robert Peterson; Yi Wang; Zhiping Li; Yonghao Gui; Jane Schaller
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  Where physicians look for information on drug prescribing for children.

Authors:  Doreen M Matsui; Mary Elizabeth Jardine; Erin Steer; Victoria Cukernik; Michael J Rieder
Journal:  Paediatr Child Health       Date:  2003-04       Impact factor: 2.253

5.  The physician's role and responsibility in reporting adverse drug events in children.

Authors:  Robert G Peterson; Chris Turner
Journal:  Paediatr Child Health       Date:  2003-04       Impact factor: 2.253

6.  Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants.

Authors:  Eva Wheatley; Kathleen A Kennedy
Journal:  J Pediatr       Date:  2009-06-21       Impact factor: 4.406

7.  Patterns of Off-Label Prescribing in the Pediatric Intensive Care Unit and Prioritizing Future Research.

Authors:  Angela S Czaja; Pamela D Reiter; M Lynn Schultz; Robert J Valuck
Journal:  J Pediatr Pharmacol Ther       Date:  2015 May-Jun

8.  Ten common questions (and their answers) about off-label drug use.

Authors:  Christopher M Wittich; Christopher M Burkle; William L Lanier
Journal:  Mayo Clin Proc       Date:  2012-08-06       Impact factor: 7.616

9.  Is computerized physician order entry use associated with a decrease in hospital resource utilization in hospitals that care for children?

Authors:  Ronald J Teufel; Abby Swanson Kazley; William T Basco
Journal:  J Med Syst       Date:  2011-04-19       Impact factor: 4.460

10.  Off-label drug use in children.

Authors:  Surabhi S Jain; S B Bavdekar; Nithya J Gogtay; Pranjali A Sadawarte
Journal:  Indian J Pediatr       Date:  2008-09-22       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.